New York S 493: Provides for a transfer fee of 75% of the fair market value in dissolution or sales of a rental project or mutual company

Bill Text

Bill Search and Legislative Information | New York State Assembly 

• 

• 

• 

• 

• 

• 

• 

• 

 Skip to main content 

 New York State Assembly

 Speaker Carl E. Heastie

 --> 
 --> 

 --> 

• 
 Assembly Members 

• 
 Legislative Info 

• 
 Public Hearings 

• 
 Speaker's Press 

• 
 Assembly Reports 

• 
 Committees & More 

• Bill Search Home
• Laws
• Legislative Calendar
• Public Hearing Schedule
• Assembly Calendars
• Assembly Committee Agenda 

 Javascript must be enabled to properly view this page. 

 Bill No.: 

• Summary 
• Actions 
• Committee&nbspVotes 
• Floor&nbspVotes 
• Memo 
• Text 
• LFIN 
• Chamber&nbspVideo/Transcript 
S00493 Summary:

BILL NOS00493 

&nbsp

SAME ASSAME AS A03116

&nbsp

SPONSORFERNANDEZ

&nbsp

COSPNSRBORRELLO

&nbsp

MLTSPNSR

&nbsp

Add §§3309-c & 3309-d, Pub Health L

&nbsp

Requires health practitioners to discuss with patients the risks associated with certain pain medications before prescribing such medications; requires that for the first opioid analgesic prescription of a calendar year the prescribing physician shall counsel the patient on the risks of overdose.

Go to top S00493 Actions:

BILL NOS00493 

&nbsp

01/08/2025REFERRED TO HEALTH

01/07/2026REFERRED TO HEALTH

Go to topS00493 Committee&nbspVotes:

Go to topS00493 Floor&nbspVotes:

There are no Assembly votes for this bill in this legislative session.

Go to topS00493 Text:

 STATE OF NEW YORK
 ________________________________________________________________________

 493

 2025-2026 Regular Sessions

 IN SENATE

 (Prefiled)

 January 8, 2025
 ___________

 Introduced by Sens. FERNANDEZ, BORRELLO -- read twice and ordered print-
 ed, and when printed to be committed to the Committee on Health

 AN ACT to amend the public health law, in relation to requiring health
 practitioners to discuss with patients the risks associated with
 certain pain medications before prescribing such medications; and in
 relation to opioid analgesic prescriptions

 The People of the State of New York, represented in Senate and Assem-
 bly, do enact as follows:

 1 Section 1. The public health law is amended by adding a new section
 2 3309-c to read as follows:
 3 § 3309-c. Practitioner and patient discussions; opioid prescriptions.
 4 1. Prior to issuing the initial prescription of a Schedule II controlled
 5 substance for the treatment of pain or any other opioid drug which is a
 6 prescription drug for acute or chronic pain and again prior to issuing
 7 the third prescription of the course of treatment, a practitioner shall
 8 discuss with the patient, or the patient's parent or guardian if the
 9 patient is under eighteen years of age and is not an emancipated minor,
 10 the risks associated with the drugs being prescribed, including but not
 11 limited to:
 12 (a) the risks of addiction and overdose associated with opioid drugs
 13 and the dangers of taking opioid drugs with alcohol, benzodiazepines and
 14 other central nervous system depressants;
 15 (b) the reasons why the prescription is necessary;
 16 (c) alternative treatments that may be available; and
 17 (d) the risks associated with the use of the drugs being prescribed,
 18 specifically that opioids are highly addictive, even when taken as
 19 prescribed, that there is a risk of developing a physical or psycholog-
 20 ical dependence on the controlled substance, and that the risks of
 21 taking more opioids than prescribed, or mixing sedatives, benzodiaze-

 EXPLANATION--Matter in italics (underscored) is new; matter in brackets
 [ ] is old law to be omitted.
 LBD01849-01-5

 S. 493 2

 1 pines or alcohol with opioids, can result in fatal respiratory
 2 depression.
 3 2. The department shall develop and make available to practitioners
 4 guidelines for the discussion required by this section.
 5 § 2. The public health law is amended by adding a new section 3309-d
 6 to read as follows:
 7 § 3309-d. Opioid analgesic prescription. 1. For the first opioid anal-
 8 gesic prescription of a calendar year that is greater than a one week's
 9 supply, the prescribing physician shall counsel the patient on the risks
 10 of overdose, and inform the patient of the availability of an opioid
 11 antagonist, including, but not limited to, naloxone.
 12 2. For the purposes of this section, the following terms shall have
 13 the following meanings:
 14 (a) "Opioid analgesics" means the medicines buprenorphine, butorpha-
 15 nol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine,
 16 methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine,
 17 propoxyphene as well as their brand names, isomers and combinations.
 18 (b) "Opioid antagonist" means an FDA-approved drug that, when adminis-
 19 tered, negates or neutralizes in whole or in part the pharmacological
 20 effects of an opioid in the body. The opioid antagonist is limited to
 21 naloxone or other medications approved by the department for this
 22 purpose.
 23 § 3. This act shall take e